CYPEX Limited

CYPEX Limited, established in 1998 in the United Kingdom, specializes in the production of cost-effective and consistent recombinant drug-metabolizing enzymes. With the slogan "Cost-effective and consistent enzymes you can trust," Cypex has positioned itself as a leading manufacturer of Phase I and Phase II enzymes. The company's core technology, developed during an extensive research program at the University of Dundee, has received funding from the UK Research Council (BBSRC) and a consortium of pharmaceutical companies. Cypex’s products play a crucial role in the pharmaceutical and biotech industries, as well as contract research organizations and academic groups. Their offerings are used to characterize CYP phenotype and metabolic routes, as well as to investigate drug interaction liabilities. Additionally, the company provides contract services from its headquarters at the Medipark in Dundee. Cypex's product portfolio includes a wide range of human, rodent, dog, pig, and monkey enzymes, along with allelic variants. Moreover, the company has fulfilled contracts for enzymes not available elsewhere and offers CYP substrates, inhibitors, and antibodies. Operating under a quality system accredited to ISO9001:2015, Cypex has gained recognition for its commitment to high standards. However, there is no public information available at this time regarding the company's last investment or the involved investors. CYP has carved out a niche in the biotechnology and manufacturing sectors, with a strong track record and a promising future in the enzyme production market.